Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that specifically binds to human CD162 (PSGL-1). this binding leads to the downregulation and apoptosis of activated T cells, a mechanism currently in clinical development for the treatment of steroid-refractory acute graft-versus-host disease (GVHD), psoriasis, psoriatic arthritis, and ulcerative colitis.
Reinheit:
95%
CAS Nummer:
[2158362-38-8]
Target-Kategorie:
Apoptosis|||Others
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten